Jacobs Levy Equity Management
CHRS icon

Jacobs Levy Equity Management’s Coherus Oncology CHRS Stock Holding History

Jacobs Levy Equity Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-252,330
Closed -$262K – 951
2024
Q3 		$262K Sell
252,330
-748,727
-75% -$1.03M ﹤0.01% 902
2024
Q2 		$1.73M Buy
+1,001,057
New +$2.01M 0.01% 628
2024
Q1 		– Sell
-1,614,278
Closed -$5.38M – 952
2023
Q4 		$5.38M Buy
1,614,278
+1,425,343
+754% +$3.82M 0.03% 413
2023
Q3 		$707K Buy
+188,935
New +$873K ﹤0.01% 737
2023
Q2 		– Sell
-519,505
Closed -$3.55M – 985
2023
Q1 		$3.55M Sell
519,505
-243,897
-32% -$1.89M 0.02% 468
2022
Q4 		$6.05M Buy
763,402
+191,555
+33% +$1.47M 0.04% 361
2022
Q3 		$5.5M Sell
571,847
-316,737
-36% -$3.21M 0.04% 376
2022
Q2 		$6.43M Buy
+888,584
New +$7.73M 0.05% 373
2021
Q4 		– Sell
-141,652
Closed -$2.28M – 984
2021
Q3 		$2.28M Buy
141,652
+3,101
+2% +$45.5K 0.02% 589
2021
Q2 		$1.92M Sell
138,551
-626,638
-82% -$8.87M 0.01% 608
2021
Q1 		$11.2M Buy
765,189
+515,055
+206% +$8.74M 0.09% 271
2020
Q4 		$4.35M Buy
250,134
+100,489
+67% +$1.79M 0.04% 423
2020
Q3 		$2.74M Buy
149,645
+37,560
+34% +$699K 0.03% 461
2020
Q2 		$2M Sell
112,085
-43,641
-28% -$739K 0.02% 532
2020
Q1 		$2.53M Sell
155,726
-111,424
-42% -$2.06M 0.03% 430
2019
Q4 		$4.81M Buy
267,150
+109,019
+69% +$2.01M 0.05% 382
2019
Q3 		$3.2M Buy
158,131
+20,540
+15% +$410K 0.04% 414
2019
Q2 		$3.04M Buy
137,591
+43,005
+45% +$747K 0.04% 443
2019
Q1 		$1.29M Buy
94,586
+44,100
+87% +$588K 0.02% 608
2018
Q4 		$457K Sell
50,486
-31,725
-39% -$367K 0.01% 745
2018
Q3 		$1.36M Buy
82,211
+15,155
+23% +$269K 0.02% 593
2018
Q2 		$939K Buy
67,056
+33,550
+100% +$480K 0.01% 679
2018
Q1 		$370K Buy
+33,506
New +$367K 0.01% 828
2016
Q3 		– Sell
-12,800
Closed -$216K – 1025
2016
Q2 		$216K Buy
+12,800
New +$240K ﹤0.01% 992

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Jacobs Levy Equity Management's CHRS Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 252,330 shares — an estimated $262K sold.

Jacobs Levy Equity Management first reported a position in CHRS in Q2 2016 and held it in 24 quarters. The position peaked at $11.2M in Q1 2021. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 252,330 Coherus Oncology shares in Q4 2024, an estimated $262K.
  • Jacobs Levy Equity Management first reported a position in Coherus Oncology in Q2 2016 and held it in 24 quarters.
  • Jacobs Levy Equity Management's Coherus Oncology position peaked at $11.2M in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.